IHC of ASCL2 was performed in 338 glioma specimens, ROC analysis was performed to determine the cutoff value, and Kaplan–Meier survival analysis indicated that patients with high ASCL2 expression exhibited poorer overall survival than those with low ASCL2 expression (Figure S6C, Supporting Information). This evidence concerns the gene ASCL2 and central nervous system cancer.